{"parse":{"title":"Emberger syndrome","pageid":57392784,"revid":849052049,"text":{"*":"<div class=\"mw-parser-output\"><p>The <b>Emberger syndrome</b> is a rare, <a href=\"/wiki/Autosomal_dominant\" class=\"mw-redirect\" title=\"Autosomal dominant\">autosomal dominant</a>, <a href=\"/wiki/Genetic_disorder\" title=\"Genetic disorder\">genetic disorder</a> caused by familial or sporadic <a href=\"/wiki/Gain-of-function_mutation\" class=\"mw-redirect\" title=\"Gain-of-function mutation\">inactivating mutations</a> in one of the two parental <i><a href=\"/wiki/GATA2\" title=\"GATA2\">GATA2</a></i> genes. The mutation results in a <a href=\"/wiki/Haploinsufficiency\" title=\"Haploinsufficiency\">haploinsufficiency</a> (i.e. reduction) in the levels of the gene's product, the GATA2 <a href=\"/wiki/Transcription_factor\" title=\"Transcription factor\">transcription factor</a>. This transcription factor is critical for the <a href=\"/wiki/Embryogenesis\" title=\"Embryogenesis\">embryonic development</a>, maintenance, and functionality of <a href=\"/wiki/Blood\" title=\"Blood\">blood-forming</a>, <a href=\"/wiki/Lymphatic_system\" title=\"Lymphatic system\">lympathic-forming</a>, and other tissues. The syndrome includes as its primarily symptoms serious abnormalities of the <a href=\"/wiki/Hematological_disorders\" class=\"mw-redirect\" title=\"Hematological disorders\">blood</a> such as the <a href=\"/wiki/Myelodysplastic_syndrome\" title=\"Myelodysplastic syndrome\">myelodysplastic syndrome</a> and <a href=\"/wiki/Acute_myeloid_leukemia\" title=\"Acute myeloid leukemia\">acute myeloid leukemia</a>; <a href=\"/wiki/Lymphedema\" title=\"Lymphedema\">lymphedema</a> (i.e. <a href=\"/wiki/Fluid\" title=\"Fluid\">fluid</a> retention and tissue swelling caused by a compromised <a href=\"/wiki/Lymphatic_system\" title=\"Lymphatic system\">lymphatic system</a>) of the lower limbs, and <a href=\"/wiki/Sensorineural_hearing_loss\" title=\"Sensorineural hearing loss\">sensorineural hearing loss</a>. However, the anomalies caused by <i>GATA2</i> mutations are highly variable with some individuals showing little or no such symptoms even in old age while others exhibit non-malignant types of hematological anomalies; lymphedema in areas besides the lower limbs, little or no hearing loss; or anomalies in other tissues. The syndrome may present with relatively benign signs and/or symptoms and then progress rapidly or slowly (i.e. over years or decades) to the myelodysplastic syndrome and/or acute myeloid leukemia. Alternatively, it may present with one of the latter two life-threatening disorders.<sup id=\"cite_ref-pmid28179280_1-0\" class=\"reference\"><a href=\"#cite_note-pmid28179280-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid29189513_2-0\" class=\"reference\"><a href=\"#cite_note-pmid29189513-2\">&#91;2&#93;</a></sup>\n</p><p>The Emberger syndrome is only one of the manifestations of inactivating <i>GATA2</i> mutations. Other manifestations include: <b>1</b> <a href=\"/wiki/MonoMAC\" title=\"MonoMAC\">Monocytopenia and Mycobacterium Avium Complex</a>/Dendritic Cell, Monocyte, B and NK Lymphocyte deficiency (i.e. MonoMAC or MonoMAC/DCML); <b>2)</b> familial <a href=\"/wiki/Myelodysplastic_syndrome\" title=\"Myelodysplastic syndrome\">myelodysplastic syndrome</a>/<a href=\"/wiki/Acute_myeloid_leukemia\" title=\"Acute myeloid leukemia\">acute myeloid leukemia</a> (i.e. familial MDS/AML); <b>3)</b> <a href=\"/wiki/Chronic_myelomonocytic_leukemia\" title=\"Chronic myelomonocytic leukemia\">chronic myelomonocytic leukemia</a>; <b>4)</b> pediatric myelodysplastic syndrome; and <b>5)</b> various other hematological abnormalities such as <a href=\"/wiki/Aplastic_anemia\" title=\"Aplastic anemia\">aplastic anemia</a>, <a href=\"/wiki/Anemia\" title=\"Anemia\">anemia</a>, chronic <a href=\"/wiki/Neutropenia\" title=\"Neutropenia\">neutropenia</a>; and/or various <a href=\"/wiki/Immunodeficiency\" title=\"Immunodeficiency\">immunological defects</a>. Individuals with the Emberger syndrome may exhibit signs or symptoms that are more characteristic of the latter manifestations. Since most individuals with inactivating <i>GATA2</i> mutations progress to a <a href=\"/wiki/Leukemic\" class=\"mw-redirect\" title=\"Leukemic\">leukemic</a> disorder, the Emberger syndrome is a <a href=\"/wiki/Precancerous_condition\" title=\"Precancerous condition\">Precancerous condition</a>.<sup id=\"cite_ref-pmid28179280_1-1\" class=\"reference\"><a href=\"#cite_note-pmid28179280-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid28643018_3-0\" class=\"reference\"><a href=\"#cite_note-pmid28643018-3\">&#91;3&#93;</a></sup>\n</p><p>The age of onset and types of symptoms that occur in individuals afflicted with the Emberger syndrome are highly variable even in family members presumed to have identical <i>GATA2</i> gene mutations. This variability as well as the variability in the different manifestations of <i>GATA2</i>-inactivating mutations are not fully understood. They likely relate, at least in part, to: individual differences in the: <b>1)</b> levels of the GATA2 transcription factor which are expressed; <b>2)</b> genetic backgrounds; <b>3)</b> occurrence of illnesses or other events that stress the bone marrow; and, possibly, <b>4)</b> development of other \"secondary\" genetic abnormalities that often develop during the course of these disorders.<sup id=\"cite_ref-pmid28179280_1-2\" class=\"reference\"><a href=\"#cite_note-pmid28179280-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid28643018_3-1\" class=\"reference\"><a href=\"#cite_note-pmid28643018-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-pmid28637621_4-0\" class=\"reference\"><a href=\"#cite_note-pmid28637621-4\">&#91;4&#93;</a></sup> Because of these many complexities, recent reports have grouped together all of the different manifestations of GATA2 inactivating mutaions into a single <a href=\"/wiki/Pleiotropy\" title=\"Pleiotropy\">pleotropic</a> <a href=\"/wiki/Genetic_disorder\" title=\"Genetic disorder\">genetic disorder</a> termed <a href=\"/wiki/GATA2_deficiency\" title=\"GATA2 deficiency\">GATA2 deficiency</a>, GATA2 haploinsufficiency, or the GATA2 deficiency syndrome. Even currently, however, the Emberger syndrome (e.g. its <a href=\"/wiki/Online_Mendelian_Inheritance_in_Man\" title=\"Online Mendelian Inheritance in Man\">MIM</a> entry is #614038) and MonoMac/DCML (e.g. its MIM entry is #614172) are often classified as distinct clinical disorders.<sup id=\"cite_ref-pmid28179280_1-3\" class=\"reference\"><a href=\"#cite_note-pmid28179280-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid29189513_2-1\" class=\"reference\"><a href=\"#cite_note-pmid29189513-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid21892158_5-0\" class=\"reference\"><a href=\"#cite_note-pmid21892158-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-pmid21892158_5-1\" class=\"reference\"><a href=\"#cite_note-pmid21892158-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-pmid28179282_6-0\" class=\"reference\"><a href=\"#cite_note-pmid28179282-6\">&#91;6&#93;</a></sup> The Emberger syndrome is here considered as a distinct disorder.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#History\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">History</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#GATA2_gene\"><span class=\"tocnumber\">2</span> <span class=\"toctext\"><i>GATA2</i> gene</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#GATA2_transcription_factor\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">GATA2 transcription factor</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#Pathophysiology\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Pathophysiology</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Clinical_signs_and_symptoms\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Clinical signs and symptoms</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#Diagnosis\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Diagnosis</span></a></li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#Treatment\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">Treatment</span></a></li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#Prognosis\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">Prognosis</span></a></li>\n<li class=\"toclevel-1 tocsection-9\"><a href=\"#References\"><span class=\"tocnumber\">9</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"History\">History</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Emberger_syndrome&amp;action=edit&amp;section=1\" title=\"Edit section: History\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The Emberger syndrome was first described by J.M. Emberger in 1979 as an unusual and not previously described constellation of symptoms (sensorineural hearing loss, lower limb lymphedema, and hematological disorders) in 4 individuals from two generations of a single family.<sup id=\"cite_ref-pmid295075_7-0\" class=\"reference\"><a href=\"#cite_note-pmid295075-7\">&#91;7&#93;</a></sup> A subsequent study published in 2011 and conducted on three different families found that 8 members of these families with clinically diagnosed Emberger syndrome<sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup>  as well as six sporadic cases of individuals with this clinical diagnosis exhibited one of eight different mutations in one of their two parental <i>GATA2</i> genes. Each mutation was predicted to reduce the levels of functional GATA2. Thus, reduced levels of functionally competent GATA2 transcription factor resulting from a mutation in one of its genes is responsible for the Emberger syndrome.<sup id=\"cite_ref-pmid21892158_5-2\" class=\"reference\"><a href=\"#cite_note-pmid21892158-5\">&#91;5&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"GATA2_gene\"><i>GATA2</i> gene</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Emberger_syndrome&amp;action=edit&amp;section=2\" title=\"Edit section: GATA2 gene\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><i>GATA2</i> is a member of the evolutionarily conserved <a href=\"/wiki/GATA_transcription_factor\" title=\"GATA transcription factor\">GATA transcription factor</a> family of genes:: all tested <a href=\"/wiki/Vertebrates\" class=\"mw-redirect\" title=\"Vertebrates\">vertebrates</a> express six <i>GATA genes</i>.<sup id=\"cite_ref-pmid23048181_9-0\" class=\"reference\"><a href=\"#cite_note-pmid23048181-9\">&#91;9&#93;</a></sup> The human <i>GATA2</i> gene is located on the long arm (or \"q\" arm) of <a href=\"/wiki/Chromosome_3\" title=\"Chromosome 3\">chromosome 3</a> at position 21.3 (i.e. located at 3q21.3).<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup><sup id=\"cite_ref-pmid28637621_4-1\" class=\"reference\"><a href=\"#cite_note-pmid28637621-4\">&#91;4&#93;</a></sup> In humans, it is <a href=\"/wiki/Gene_expression\" title=\"Gene expression\">expressed</a> in hematologic cells at the <a href=\"/wiki/Stem_cell\" title=\"Stem cell\">stem cell</a> and later <a href=\"/wiki/Progenitor_cell\" title=\"Progenitor cell\">progenitor cell</a> stages of their <a href=\"/wiki/Cellular_differentiation\" title=\"Cellular differentiation\">development</a>. Increases and/or decreases in the gene's expression regulate the progression of these immature cells toward their final forms as blood cells such as <a href=\"/wiki/Erythrocytes\" class=\"mw-redirect\" title=\"Erythrocytes\">erythrocytess</a>, certain types of <a href=\"/wiki/Lymphocyte\" title=\"Lymphocyte\">lymphocytes</a>, <a href=\"/wiki/Monocyte\" title=\"Monocyte\">monocytes</a>, and <a href=\"/wiki/Platelet\" title=\"Platelet\">platelets</a>) as well as certain types of tissue cells such as <a href=\"/wiki/Macrophages\" class=\"mw-redirect\" title=\"Macrophages\">macrophages</a> and mast cells.<sup id=\"cite_ref-pmid28637621_4-2\" class=\"reference\"><a href=\"#cite_note-pmid28637621-4\">&#91;4&#93;</a></sup> The <i>GATA2</i> gene is also expressed in human <a href=\"/wiki/Endothelium\" title=\"Endothelium\">endothelium</a>, certain types of non-hematological stem cells, and, to lesser extents, prostate, endometrium, and some cancerous tissues.<sup id=\"cite_ref-pmid28179280_1-4\" class=\"reference\"><a href=\"#cite_note-pmid28179280-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid28637621_4-3\" class=\"reference\"><a href=\"#cite_note-pmid28637621-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-pmid23048181_9-1\" class=\"reference\"><a href=\"#cite_note-pmid23048181-9\">&#91;9&#93;</a></sup>\n</p><p><a href=\"/wiki/Monosomy\" title=\"Monosomy\">Monosomy</a> of <a href=\"/wiki/Chromosome_7\" title=\"Chromosome 7\">chromosome 7</a> (i.e. lose of one of the two chromosomes 7) or deletion of the \"q\" (i.e. short) in one of these two chromosomes often occurs in the various GATA2 deficiency manifestations including the Emberger syndrome. These genetic abnormalities are known causes of acute myeloid leukemia and, while not essential for, may contribute to the development of acute myeloid leukemia in the syndrome  by, for example, lowering the age and/or increasing the chances of the disorder evolving into acute myeloid leukemia.<sup id=\"cite_ref-pmid28637621_4-4\" class=\"reference\"><a href=\"#cite_note-pmid28637621-4\">&#91;4&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"GATA2_transcription_factor\">GATA2 transcription factor</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Emberger_syndrome&amp;action=edit&amp;section=3\" title=\"Edit section: GATA2 transcription factor\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The GATA2 transcription factor contains two <a href=\"/wiki/Zinc_finger\" title=\"Zinc finger\">zinc finger</a> (i.e. ZnF) <a href=\"/wiki/Structural_motif#In_proteins\" title=\"Structural motif\">structural motifs</a>. C-ZnF is located toward the protein's <a href=\"/wiki/C-terminus\" title=\"C-terminus\">C-terminus</a> and is responsible for binding to specific <a href=\"/wiki/DNA\" title=\"DNA\">DNA</a> sites. N-ZnF is located toward the proteins <a href=\"/wiki/N-terminus\" title=\"N-terminus\">N-terminus</a> and is responsible for interacting with various other <a href=\"/wiki/Cell_nucleus#Cell_compartmentalization\" title=\"Cell nucleus\">nuclear proteins</a> that regulate its activity. The transcription factor also contains two <a href=\"/wiki/Transactivation_domain\" title=\"Transactivation domain\">transactivation domains</a> and one negative regulatory domain which interact with nuclear proteins to up-regulate and down-regulate, respectively, its activity.<sup id=\"cite_ref-pmid28637621_4-5\" class=\"reference\"><a href=\"#cite_note-pmid28637621-4\">&#91;4&#93;</a></sup>\n</p><p>GATA2 binds to a specific <a href=\"/wiki/Nucleic_acid_sequence\" title=\"Nucleic acid sequence\">nucleic acid sequence</a>  viz., (T/A(GATA)A/G) on the <a href=\"/wiki/Promoter_(genetics)\" title=\"Promoter (genetics)\">promoter</a> and <a href=\"/wiki/Enhancer_(genetics)\" title=\"Enhancer (genetics)\">enhancer</a> sites of its target genes and in doing so either stimulates or suppresses these genes' expression. However, there are thousands of sites in human DNA with this nucleotide sequence but, for unknown reasons, GATA2 binds to &lt;1% of these. Furthermore, all members of the GATA transcription factor family bind to this same nucleotide sequence and in doing so may interfere with GATA2 binding or even displace GATA2 already bound to these sites. For example, the displacement of GATA2 bond to this sequence by GATA1 appears important for the normal development of certain hematological stem cells. This phenomenon is termed the \"GATA switch\". Given these many variables, the GATA2 transcription factor's actions in promoting or inhibiting its target genes is exceedingly complex and not completely understood.<sup id=\"cite_ref-pmid28179280_1-5\" class=\"reference\"><a href=\"#cite_note-pmid28179280-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid28637621_4-6\" class=\"reference\"><a href=\"#cite_note-pmid28637621-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-pmid28179282_6-1\" class=\"reference\"><a href=\"#cite_note-pmid28179282-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-pmid20803646_11-0\" class=\"reference\"><a href=\"#cite_note-pmid20803646-11\">&#91;11&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Pathophysiology\">Pathophysiology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Emberger_syndrome&amp;action=edit&amp;section=4\" title=\"Edit section: Pathophysiology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The GATA2 transcription factor is critical for the emergence of hematologic stem cells from the <a href=\"/wiki/Hemogenic_endothelium\" title=\"Hemogenic endothelium\">hemogenic endothelium</a> during <a href=\"/wiki/Embryogenesis\" title=\"Embryogenesis\">embryogenesis</a>. Deletion of both <i>Gata2</i> genes in mice is lethal by about day 10 of embryogenesis due to collapse in the <a href=\"/wiki/Hematopoiesis\" class=\"mw-redirect\" title=\"Hematopoiesis\">formation of mature blood cells</a>. Inactivation of one mouse <i>Gata2</i> gene is neither lethal nor associated with most of the signs of human GATA2 deficiency except that these animals have ~50% reduction in their hematologic stem cells. The latter findings as well as clinical studies in vitro experiments on human tissues support the notion that both parental <i>GATA2</i> genes are needed to produce levels of the GATA2 transcription factor sufficient for developing and maintaining normal levels of hematological stem and progenitor cells in humans.<sup id=\"cite_ref-pmid28637621_4-7\" class=\"reference\"><a href=\"#cite_note-pmid28637621-4\">&#91;4&#93;</a></sup> The transcription factor's role in performing this function involves complex and incompletely understood interactions with a network of hematopoietic transcription factors including <a href=\"/wiki/RUNX1\" title=\"RUNX1\">RUNX1</a>, <a href=\"/wiki/TAL1\" title=\"TAL1\">TAL1</a>, <a href=\"/wiki/MYB_(gene)\" title=\"MYB (gene)\">MYB</a>, <a href=\"/wiki/GFI1\" title=\"GFI1\">GFI1</a>, <a href=\"/wiki/FLI1\" title=\"FLI1\">FLI1</a>, <a href=\"/wiki/LYL1\" title=\"LYL1\">LYL1</a>, and <a href=\"/wiki/PU.1\" class=\"mw-redirect\" title=\"PU.1\">PU.1</a>. It is not exactly clear how <a href=\"/wiki/Haploinsufficiency\" title=\"Haploinsufficiency\">reduced levels</a> of GATA2 cause any of Emberger syndrome's hematological disorders.<sup id=\"cite_ref-pmid28179282_6-2\" class=\"reference\"><a href=\"#cite_note-pmid28179282-6\">&#91;6&#93;</a></sup>\n</p><p>The role of GATA2 in promoting the normal development of the lymphatic stem cells may be responsible for the other two key features of the Emberger syndrome. That is, failure to develop competent valves and/or vessels in the <a href=\"/wiki/Lymphatic_system\" title=\"Lymphatic system\">lymphatic system</a>, it is proposed, is responsible for the lymphedema of Emberger syndrome while failure to generate the <a href=\"/wiki/Perilymphatic_space\" class=\"mw-redirect\" title=\"Perilymphatic space\">perilymphatic space</a> around the inner ear's <a href=\"/wiki/Semicircular_canals\" title=\"Semicircular canals\">semicircular canals</a>, it is proposed, is responsible for the syndrome's sensorineural hearing loss.<sup id=\"cite_ref-pmid28643018_3-2\" class=\"reference\"><a href=\"#cite_note-pmid28643018-3\">&#91;3&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Clinical_signs_and_symptoms\">Clinical signs and symptoms</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Emberger_syndrome&amp;action=edit&amp;section=5\" title=\"Edit section: Clinical signs and symptoms\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The age of onset of the Emberger syndrome is variable with rare individuals showing first symptoms such as lymphedema occurring in early infancy while others are symptomless or develop first symptoms in their middle and latter years.<sup id=\"cite_ref-pmid21892158_5-3\" class=\"reference\"><a href=\"#cite_note-pmid21892158-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-pmid20803646_11-1\" class=\"reference\"><a href=\"#cite_note-pmid20803646-11\">&#91;11&#93;</a></sup> This variability can occur between members of the same family who are documented to have the same <i>GATA2</i> mutation.<sup id=\"cite_ref-pmid28271814_12-0\" class=\"reference\"><a href=\"#cite_note-pmid28271814-12\">&#91;12&#93;</a></sup> The syndrome's most common times of onset are infancy and early childhood.<sup id=\"cite_ref-pmid20803646_11-2\" class=\"reference\"><a href=\"#cite_note-pmid20803646-11\">&#91;11&#93;</a></sup> The syndrome may present with unexplained lymphedema, hearing loss, and/or hematological defects like  <a href=\"/wiki/Neutropenia\" title=\"Neutropenia\">neutropenia</a>, <a href=\"/wiki/Anemia\" title=\"Anemia\">anemia</a>, <a href=\"/wiki/Thrombocytopenia\" title=\"Thrombocytopenia\">thrombocytopenia</a>, and/or the circulation of abnormal blood cells. Other defects less commonly associated with and the syndrome include <a href=\"/wiki/Hypotelorism\" title=\"Hypotelorism\">hypotelorism</a>, <a href=\"/wiki/Epicanthic_folds\" class=\"mw-redirect\" title=\"Epicanthic folds\">epicanthic folds</a>, <a href=\"/wiki/Hydrocele\" title=\"Hydrocele\">hydrocele</a>, <a href=\"/wiki/Webbed_neck\" title=\"Webbed neck\">webbed neck</a>, and <a href=\"/wiki/Warts\" class=\"mw-redirect\" title=\"Warts\">warts</a> caused be human papillomavirus infection.<sup id=\"cite_ref-pmid28179280_1-6\" class=\"reference\"><a href=\"#cite_note-pmid28179280-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid21892158_5-4\" class=\"reference\"><a href=\"#cite_note-pmid21892158-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-pmid20803646_11-3\" class=\"reference\"><a href=\"#cite_note-pmid20803646-11\">&#91;11&#93;</a></sup> In these case of relatively benign symptoms and signs, the syndrome commonly progresses rapidly or slowly to <a href=\"/wiki/Myelodysplastic_syndrome\" title=\"Myelodysplastic syndrome\">myelodysplastic syndrome</a> followed by <a href=\"/wiki/Acute_myeloid_leukemia\" title=\"Acute myeloid leukemia\">acute myeloid leukemia</a>. Less commonly, Emberger syndrome presents with the myelodysplastic syndrome and/or acute myeloid leukemia.<sup id=\"cite_ref-pmid20803646_11-4\" class=\"reference\"><a href=\"#cite_note-pmid20803646-11\">&#91;11&#93;</a></sup><sup id=\"cite_ref-pmid25659730_13-0\" class=\"reference\"><a href=\"#cite_note-pmid25659730-13\">&#91;13&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Diagnosis\">Diagnosis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Emberger_syndrome&amp;action=edit&amp;section=6\" title=\"Edit section: Diagnosis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Examination of <a href=\"/wiki/Complete_blood_count\" title=\"Complete blood count\">circulating blood cells</a>, <a href=\"/wiki/Bone_marrow_biopsy\" class=\"mw-redirect\" title=\"Bone marrow biopsy\">bone marrow cells</a>, and the <i>GATA2</i> <a href=\"/wiki/Nucleotide_sequence\" class=\"mw-redirect\" title=\"Nucleotide sequence\">nucleotide sequence</a> of individuals with Emberger syndrome typically evidences abnormalities which are not distinctively different from those of individuals with other manifestations of GATA2 deficiency. The specific diagnosis of Emberger syndrome depends on detecting mutations of the <i>GATA2</i> gene in a setting of clinical findings of hematological disorders, lymphedema, and neurosensory hearing loss. It may be especially difficult to diagnose the syndrome in the absence of at least one of the latter two clinical signs or in individuals who exhibit anomalies strongly associated with one of the other manifestations of GATA2 deficiency. <a href=\"/wiki/DNA_sequencing\" title=\"DNA sequencing\">DNA sequencing</a> of the full <i>GATA2</i> gene <a href=\"/wiki/Coding_region\" title=\"Coding region\">coding region</a> including the <a href=\"/wiki/Intron\" title=\"Intron\">intron</a>4 enhancer by <a href=\"/wiki/Sanger_sequencing\" title=\"Sanger sequencing\">Sanger sequencing</a> or <a href=\"/wiki/High-throughput_sequencing\" class=\"mw-redirect\" title=\"High-throughput sequencing\">high-throughput</a> methods along with DNA <a href=\"/wiki/Copy_number_analysis\" title=\"Copy number analysis\">copy number analysis</a> should establish the presence of <i>GATA2</i> gene mutations; comparison of detected gene mutations to the list of inactivating GATA2 gene mutations plus the clinical presentation and family history are essentials in making the diagnosis of the syndrome and its type of presentation.<sup id=\"cite_ref-pmid29189513_2-2\" class=\"reference\"><a href=\"#cite_note-pmid29189513-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid21892158_5-5\" class=\"reference\"><a href=\"#cite_note-pmid21892158-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-pmid25659730_13-1\" class=\"reference\"><a href=\"#cite_note-pmid25659730-13\">&#91;13&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Treatment\">Treatment</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Emberger_syndrome&amp;action=edit&amp;section=7\" title=\"Edit section: Treatment\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Standard measures are use for <a href=\"/wiki/Lymphedema#Treatment\" title=\"Lymphedema\">the treatment of lymphedema</a>, <a href=\"/wiki/Sensorineural_hearing_loss#Treatment\" title=\"Sensorineural hearing loss\">sensorineural hearing loss</a>, and the other non-malignant anomalies associated with the Emberger syndrome. However, treatment of the disorder's myelodysplastic syndrome and acute myeloid leukemia differs somewhat from standard measures. Like other GATA2 insufficiencies, Emberger syndrome is associated with a deficiency of hematological stem and early progenitor cells that is often due to a hereditary loss of one <i>GATA2</i> gene.<sup id=\"cite_ref-pmid28637621_4-8\" class=\"reference\"><a href=\"#cite_note-pmid28637621-4\">&#91;4&#93;</a></sup> Consequently, the use of radical <a href=\"/wiki/Hematopoietic_stem_cell_transplantation#Conditioning_regimens#Myeloablative\" title=\"Hematopoietic stem cell transplantation\">myeloablative</a> conditioning regimens to remove native bone marrow stem/progenitor cells in preparation for <a href=\"/wiki/Hematopoietic_stem_cell_transplantation\" title=\"Hematopoietic stem cell transplantation\">hematopoietic stem cell transplantation</a> may entail excessive morbidity and mortality. While no controlled studies on the treatment of the hematological disorders of the syndrome have been reported, current recommendations by multiple authorities suggest the use of <a href=\"/wiki/Hematopoietic_stem_cell_transplantation\" title=\"Hematopoietic stem cell transplantation\">hematopoietic stem cell transplantation</a> using <a href=\"/wiki/Hematopoietic_stem_cell_transplantation#Conditioning_regimens#Non-myeloablative\" title=\"Hematopoietic stem cell transplantation\">non-myeloablative</a> conditioning methods be used when indicated. The use of this procedure should be anticipatory and occur before the development of an excess of <a href=\"/wiki/Progenitor_cells\" class=\"mw-redirect\" title=\"Progenitor cells\">progenitor cells</a> populate the bone marrow in cases of myelodyspasia as well as before the development of acute myeloid leukemia. Accordingly, individuals should be routinely monitored by <a href=\"/wiki/Bone_marrow_examination\" title=\"Bone marrow examination\">bone marrow examinations</a> and <a href=\"/wiki/Complete_blood_count\" title=\"Complete blood count\">complete blood counts</a>. Furthermore, the relatives of patients afflicted with the syndrome or any of other manifestations of GATA2 deficiency should be tested for <i>GATA2</i> mutations. Individuals with such mutations are not candidates for donating their stem cells of Emberger syndrome patients.<sup id=\"cite_ref-pmid28179280_1-7\" class=\"reference\"><a href=\"#cite_note-pmid28179280-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid29189513_2-3\" class=\"reference\"><a href=\"#cite_note-pmid29189513-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid28643018_3-3\" class=\"reference\"><a href=\"#cite_note-pmid28643018-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-pmid28637621_4-9\" class=\"reference\"><a href=\"#cite_note-pmid28637621-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-pmid25659730_13-2\" class=\"reference\"><a href=\"#cite_note-pmid25659730-13\">&#91;13&#93;</a></sup><sup id=\"cite_ref-pmid25397911_14-0\" class=\"reference\"><a href=\"#cite_note-pmid25397911-14\">&#91;14&#93;</a></sup> Reversion of the bone marrow to full immune restitution with improved expression of GATA2 can take up to several years after transplantation.<sup id=\"cite_ref-pmid28179280_1-8\" class=\"reference\"><a href=\"#cite_note-pmid28179280-1\">&#91;1&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Prognosis\">Prognosis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Emberger_syndrome&amp;action=edit&amp;section=8\" title=\"Edit section: Prognosis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Prognosis of the Emberger syndrome depends heavily on the speed of its progression to <a href=\"/wiki/Bone_marrow_failure\" title=\"Bone marrow failure\">bone marrow failure</a>, myelodysplasia with excessive blast cells, or acute myeloid leukemia. Intervention with <a href=\"/wiki/Hematopoietic_stem_cell_transplantation#Conditioning_regimens#Non-myeloablative\" title=\"Hematopoietic stem cell transplantation\">non-myeloablative hematopoietic stem cell transplantation</a> before development of the latter two disorders is thought to improve survival indefinitely in most cases.<sup id=\"cite_ref-pmid28179280_1-9\" class=\"reference\"><a href=\"#cite_note-pmid28179280-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid29189513_2-4\" class=\"reference\"><a href=\"#cite_note-pmid29189513-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid28643018_3-4\" class=\"reference\"><a href=\"#cite_note-pmid28643018-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-pmid28637621_4-10\" class=\"reference\"><a href=\"#cite_note-pmid28637621-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-pmid25659730_13-3\" class=\"reference\"><a href=\"#cite_note-pmid25659730-13\">&#91;13&#93;</a></sup><sup id=\"cite_ref-pmid25397911_14-1\" class=\"reference\"><a href=\"#cite_note-pmid25397911-14\">&#91;14&#93;</a></sup> While not yet tested, this transplantation intervention would seem to offer a similar benefit in cases of severe, potentially lethal bone marrow failure.\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Emberger_syndrome&amp;action=edit&amp;section=9\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap mw-references-columns\"><ol class=\"references\">\n<li id=\"cite_note-pmid28179280-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid28179280_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid28179280_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid28179280_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid28179280_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid28179280_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-pmid28179280_1-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-pmid28179280_1-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-pmid28179280_1-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-pmid28179280_1-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-pmid28179280_1-9\"><sup><i><b>j</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Crispino JD, Horwitz MS (April 2017). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5391620\">\"GATA factor mutations in hematologic disease\"</a>. <i>Blood</i>. <b>129</b> (15): 2103\u20132110. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1182/blood-2016-09-687889\">10.1182/blood-2016-09-687889</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5391620\">5391620</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28179280\">28179280</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Blood&amp;rft.atitle=GATA+factor+mutations+in+hematologic+disease&amp;rft.volume=129&amp;rft.issue=15&amp;rft.pages=2103-2110&amp;rft.date=2017-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5391620&amp;rft_id=info%3Apmid%2F28179280&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2016-09-687889&amp;rft.aulast=Crispino&amp;rft.aufirst=JD&amp;rft.au=Horwitz%2C+MS&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5391620&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid29189513-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid29189513_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid29189513_2-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid29189513_2-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid29189513_2-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid29189513_2-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Rastogi N, Abraham RS, Chadha R, Thakkar D, Kohli S, Nivargi S, Prakash Yadav S (November 2017). \"Successful Nonmyeloablative Allogeneic Stem Cell Transplant in a Child With Emberger Syndrome and GATA2 Mutation\". <i>Journal of Pediatric Hematology/oncology</i>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/MPH.0000000000000995\">10.1097/MPH.0000000000000995</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/29189513\">29189513</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Pediatric+Hematology%2Foncology&amp;rft.atitle=Successful+Nonmyeloablative+Allogeneic+Stem+Cell+Transplant+in+a+Child+With+Emberger+Syndrome+and+GATA2+Mutation&amp;rft.date=2017-11&amp;rft_id=info%3Adoi%2F10.1097%2FMPH.0000000000000995&amp;rft_id=info%3Apmid%2F29189513&amp;rft.aulast=Rastogi&amp;rft.aufirst=N&amp;rft.au=Abraham%2C+RS&amp;rft.au=Chadha%2C+R&amp;rft.au=Thakkar%2C+D&amp;rft.au=Kohli%2C+S&amp;rft.au=Nivargi%2C+S&amp;rft.au=Prakash+Yadav%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28643018-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid28643018_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid28643018_3-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid28643018_3-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid28643018_3-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid28643018_3-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM (August 2017). \"Heterogeneity of GATA2-related myeloid neoplasms\". <i>International Journal of Hematology</i>. <b>106</b> (2): 175\u2013182. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/s12185-017-2285-2\">10.1007/s12185-017-2285-2</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28643018\">28643018</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Hematology&amp;rft.atitle=Heterogeneity+of+GATA2-related+myeloid+neoplasms&amp;rft.volume=106&amp;rft.issue=2&amp;rft.pages=175-182&amp;rft.date=2017-08&amp;rft_id=info%3Adoi%2F10.1007%2Fs12185-017-2285-2&amp;rft_id=info%3Apmid%2F28643018&amp;rft.aulast=Hirabayashi&amp;rft.aufirst=S&amp;rft.au=Wlodarski%2C+MW&amp;rft.au=Kozyra%2C+E&amp;rft.au=Niemeyer%2C+CM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28637621-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid28637621_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid28637621_4-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid28637621_4-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid28637621_4-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid28637621_4-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-pmid28637621_4-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-pmid28637621_4-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-pmid28637621_4-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-pmid28637621_4-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-pmid28637621_4-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-pmid28637621_4-10\"><sup><i><b>k</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Wlodarski MW, Collin M, Horwitz MS (April 2017). \"GATA2 deficiency and related myeloid neoplasms\". <i>Seminars in Hematology</i>. <b>54</b> (2): 81\u201386. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1053/j.seminhematol.2017.05.002\">10.1053/j.seminhematol.2017.05.002</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28637621\">28637621</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Seminars+in+Hematology&amp;rft.atitle=GATA2+deficiency+and+related+myeloid+neoplasms&amp;rft.volume=54&amp;rft.issue=2&amp;rft.pages=81-86&amp;rft.date=2017-04&amp;rft_id=info%3Adoi%2F10.1053%2Fj.seminhematol.2017.05.002&amp;rft_id=info%3Apmid%2F28637621&amp;rft.aulast=Wlodarski&amp;rft.aufirst=MW&amp;rft.au=Collin%2C+M&amp;rft.au=Horwitz%2C+MS&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid21892158-5\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid21892158_5-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid21892158_5-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid21892158_5-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid21892158_5-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid21892158_5-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-pmid21892158_5-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, Woollard WJ, Dafou D, Kilo T, Smithson S, Lunt P, Murday VA, Hodgson S, Keenan R, Pilz DT, Martinez-Corral I, Makinen T, Mortimer PS, Jeffery S, Trembath RC, Mansour S (September 2011). \"Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)\". <i>Nature Genetics</i>. <b>43</b> (10): 929\u201331. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/ng.923\">10.1038/ng.923</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/21892158\">21892158</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Genetics&amp;rft.atitle=Mutations+in+GATA2+cause+primary+lymphedema+associated+with+a+predisposition+to+acute+myeloid+leukemia+%28Emberger+syndrome%29&amp;rft.volume=43&amp;rft.issue=10&amp;rft.pages=929-31&amp;rft.date=2011-09&amp;rft_id=info%3Adoi%2F10.1038%2Fng.923&amp;rft_id=info%3Apmid%2F21892158&amp;rft.aulast=Ostergaard&amp;rft.aufirst=P&amp;rft.au=Simpson%2C+MA&amp;rft.au=Connell%2C+FC&amp;rft.au=Steward%2C+CG&amp;rft.au=Brice%2C+G&amp;rft.au=Woollard%2C+WJ&amp;rft.au=Dafou%2C+D&amp;rft.au=Kilo%2C+T&amp;rft.au=Smithson%2C+S&amp;rft.au=Lunt%2C+P&amp;rft.au=Murday%2C+VA&amp;rft.au=Hodgson%2C+S&amp;rft.au=Keenan%2C+R&amp;rft.au=Pilz%2C+DT&amp;rft.au=Martinez-Corral%2C+I&amp;rft.au=Makinen%2C+T&amp;rft.au=Mortimer%2C+PS&amp;rft.au=Jeffery%2C+S&amp;rft.au=Trembath%2C+RC&amp;rft.au=Mansour%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28179282-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid28179282_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid28179282_6-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid28179282_6-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Katsumura KR, Bresnick EH (April 2017). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5391619\">\"The GATA factor revolution in hematology\"</a>. <i>Blood</i>. <b>129</b> (15): 2092\u20132102. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1182/blood-2016-09-687871\">10.1182/blood-2016-09-687871</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5391619\">5391619</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28179282\">28179282</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Blood&amp;rft.atitle=The+GATA+factor+revolution+in+hematology&amp;rft.volume=129&amp;rft.issue=15&amp;rft.pages=2092-2102&amp;rft.date=2017-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5391619&amp;rft_id=info%3Apmid%2F28179282&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2016-09-687871&amp;rft.aulast=Katsumura&amp;rft.aufirst=KR&amp;rft.au=Bresnick%2C+EH&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5391619&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid295075-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid295075_7-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Emberger JM, Navarro M, Dejean M, Izarn P (October 1979). \"[Deaf-mutism, lymphedema of the lower limbs and hematological abnormalities (acute leukemia, cytopenia) with autosomal dominant transmission]\". <i>Journal De Genetique Humaine</i> (in French). <b>27</b> (3): 237\u201345. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/295075\">295075</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+De+Genetique+Humaine&amp;rft.atitle=%5BDeaf-mutism%2C+lymphedema+of+the+lower+limbs+and+hematological+abnormalities+%28acute+leukemia%2C+cytopenia%29+with+autosomal+dominant+transmission%5D&amp;rft.volume=27&amp;rft.issue=3&amp;rft.pages=237-45&amp;rft.date=1979-10&amp;rft_id=info%3Apmid%2F295075&amp;rft.aulast=Emberger&amp;rft.aufirst=JM&amp;rft.au=Navarro%2C+M&amp;rft.au=Dejean%2C+M&amp;rft.au=Izarn%2C+P&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Ostergaard, P; Simpson, MA; Connell, FC; Steward, CG; Brice, G; Woollard, WJ; Dafou, D; Kilo, T; Smithson, S; Lunt, P; Murday, VA; Hodgson, S; Keenan, R; Pilz, DT; Martinez-Corral, I; Makinen, T; Mortimer, PS; Jeffery, S; Trembath, RC; Mansour, S (4 September 2011). \"Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)\". <i>Nature Genetics</i>. <b>43</b> (10): 929\u201331. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/ng.923\">10.1038/ng.923</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/21892158\">21892158</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Genetics&amp;rft.atitle=Mutations+in+GATA2+cause+primary+lymphedema+associated+with+a+predisposition+to+acute+myeloid+leukemia+%28Emberger+syndrome%29.&amp;rft.volume=43&amp;rft.issue=10&amp;rft.pages=929-31&amp;rft.date=2011-09-04&amp;rft_id=info%3Adoi%2F10.1038%2Fng.923&amp;rft_id=info%3Apmid%2F21892158&amp;rft.aulast=Ostergaard&amp;rft.aufirst=P&amp;rft.au=Simpson%2C+MA&amp;rft.au=Connell%2C+FC&amp;rft.au=Steward%2C+CG&amp;rft.au=Brice%2C+G&amp;rft.au=Woollard%2C+WJ&amp;rft.au=Dafou%2C+D&amp;rft.au=Kilo%2C+T&amp;rft.au=Smithson%2C+S&amp;rft.au=Lunt%2C+P&amp;rft.au=Murday%2C+VA&amp;rft.au=Hodgson%2C+S&amp;rft.au=Keenan%2C+R&amp;rft.au=Pilz%2C+DT&amp;rft.au=Martinez-Corral%2C+I&amp;rft.au=Makinen%2C+T&amp;rft.au=Mortimer%2C+PS&amp;rft.au=Jeffery%2C+S&amp;rft.au=Trembath%2C+RC&amp;rft.au=Mansour%2C+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid23048181-9\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid23048181_9-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid23048181_9-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Chlon TM, Crispino JD (November 2012). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3472596\">\"Combinatorial regulation of tissue specification by GATA and FOG factors\"</a>. <i>Development</i>. <b>139</b> (21): 3905\u201316. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1242/dev.080440\">10.1242/dev.080440</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3472596\">3472596</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23048181\">23048181</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Development&amp;rft.atitle=Combinatorial+regulation+of+tissue+specification+by+GATA+and+FOG+factors&amp;rft.volume=139&amp;rft.issue=21&amp;rft.pages=3905-16&amp;rft.date=2012-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3472596&amp;rft_id=info%3Apmid%2F23048181&amp;rft_id=info%3Adoi%2F10.1242%2Fdev.080440&amp;rft.aulast=Chlon&amp;rft.aufirst=TM&amp;rft.au=Crispino%2C+JD&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3472596&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"https://www.ncbi.nlm.nih.gov/gene/2624\">https://www.ncbi.nlm.nih.gov/gene/2624</a></span>\n</li>\n<li id=\"cite_note-pmid20803646-11\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid20803646_11-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid20803646_11-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid20803646_11-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid20803646_11-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid20803646_11-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Mansour S, Connell F, Steward C, Ostergaard P, Brice G, Smithson S, Lunt P, Jeffery S, Dokal I, Vulliamy T, Gibson B, Hodgson S, Cottrell S, Kiely L, Tinworth L, Kalidas K, Mufti G, Cornish J, Keenan R, Mortimer P, Murday V (September 2010). \"Emberger syndrome-primary lymphedema with myelodysplasia: report of seven new cases\". <i>American Journal of Medical Genetics. Part A</i>. <b>152A</b> (9): 2287\u201396. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/ajmg.a.33445\">10.1002/ajmg.a.33445</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20803646\">20803646</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=American+Journal+of+Medical+Genetics.+Part+A&amp;rft.atitle=Emberger+syndrome-primary+lymphedema+with+myelodysplasia%3A+report+of+seven+new+cases&amp;rft.volume=152A&amp;rft.issue=9&amp;rft.pages=2287-96&amp;rft.date=2010-09&amp;rft_id=info%3Adoi%2F10.1002%2Fajmg.a.33445&amp;rft_id=info%3Apmid%2F20803646&amp;rft.aulast=Mansour&amp;rft.aufirst=S&amp;rft.au=Connell%2C+F&amp;rft.au=Steward%2C+C&amp;rft.au=Ostergaard%2C+P&amp;rft.au=Brice%2C+G&amp;rft.au=Smithson%2C+S&amp;rft.au=Lunt%2C+P&amp;rft.au=Jeffery%2C+S&amp;rft.au=Dokal%2C+I&amp;rft.au=Vulliamy%2C+T&amp;rft.au=Gibson%2C+B&amp;rft.au=Hodgson%2C+S&amp;rft.au=Cottrell%2C+S&amp;rft.au=Kiely%2C+L&amp;rft.au=Tinworth%2C+L&amp;rft.au=Kalidas%2C+K&amp;rft.au=Mufti%2C+G&amp;rft.au=Cornish%2C+J&amp;rft.au=Keenan%2C+R&amp;rft.au=Mortimer%2C+P&amp;rft.au=Murday%2C+V&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28271814-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid28271814_12-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Brambila-Tapia AJ, Garc\u00eda-Ortiz JE, Brouillard P, Nguyen HL, Vikkula M, R\u00edos-Gonz\u00e1lez BE, Sandoval-Mu\u00f1iz RJ, Sandoval-Talamantes AK, Bobadilla-Morales L, Corona-Rivera JR, Arnaud-Lopez L (September 2017). \"GATA2 null mutation associated with incomplete penetrance in a family with Emberger syndrome\". <i>Hematology (Amsterdam, Netherlands)</i>. <b>22</b> (8): 467\u2013471. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1080/10245332.2017.1294551\">10.1080/10245332.2017.1294551</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28271814\">28271814</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hematology+%28Amsterdam%2C+Netherlands%29&amp;rft.atitle=GATA2+null+mutation+associated+with+incomplete+penetrance+in+a+family+with+Emberger+syndrome&amp;rft.volume=22&amp;rft.issue=8&amp;rft.pages=467-471&amp;rft.date=2017-09&amp;rft_id=info%3Adoi%2F10.1080%2F10245332.2017.1294551&amp;rft_id=info%3Apmid%2F28271814&amp;rft.aulast=Brambila-Tapia&amp;rft.aufirst=AJ&amp;rft.au=Garc%C3%ADa-Ortiz%2C+JE&amp;rft.au=Brouillard%2C+P&amp;rft.au=Nguyen%2C+HL&amp;rft.au=Vikkula%2C+M&amp;rft.au=R%C3%ADos-Gonz%C3%A1lez%2C+BE&amp;rft.au=Sandoval-Mu%C3%B1iz%2C+RJ&amp;rft.au=Sandoval-Talamantes%2C+AK&amp;rft.au=Bobadilla-Morales%2C+L&amp;rft.au=Corona-Rivera%2C+JR&amp;rft.au=Arnaud-Lopez%2C+L&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid25659730-13\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid25659730_13-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid25659730_13-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid25659730_13-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid25659730_13-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Babushok DV, Bessler M (March 2015). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4323616\">\"Genetic predisposition syndromes: when should they be considered in the work-up of MDS?\"</a>. <i>Best Practice &amp; Research. Clinical Haematology</i>. <b>28</b> (1): 55\u201368. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.beha.2014.11.004\">10.1016/j.beha.2014.11.004</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4323616\">4323616</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25659730\">25659730</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Best+Practice+%26+Research.+Clinical+Haematology&amp;rft.atitle=Genetic+predisposition+syndromes%3A+when+should+they+be+considered+in+the+work-up+of+MDS%3F&amp;rft.volume=28&amp;rft.issue=1&amp;rft.pages=55-68&amp;rft.date=2015-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4323616&amp;rft_id=info%3Apmid%2F25659730&amp;rft_id=info%3Adoi%2F10.1016%2Fj.beha.2014.11.004&amp;rft.aulast=Babushok&amp;rft.aufirst=DV&amp;rft.au=Bessler%2C+M&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4323616&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid25397911-14\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid25397911_14-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid25397911_14-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Hsu AP, McReynolds LJ, Holland SM (February 2015). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4342850\">\"GATA2 deficiency\"</a>. <i>Current Opinion in Allergy and Clinical Immunology</i>. <b>15</b> (1): 104\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/ACI.0000000000000126\">10.1097/ACI.0000000000000126</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4342850\">4342850</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25397911\">25397911</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Opinion+in+Allergy+and+Clinical+Immunology&amp;rft.atitle=GATA2+deficiency&amp;rft.volume=15&amp;rft.issue=1&amp;rft.pages=104-9&amp;rft.date=2015-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4342850&amp;rft_id=info%3Apmid%2F25397911&amp;rft_id=info%3Adoi%2F10.1097%2FACI.0000000000000126&amp;rft.aulast=Hsu&amp;rft.aufirst=AP&amp;rft.au=McReynolds%2C+LJ&amp;rft.au=Holland%2C+SM&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4342850&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEmberger+syndrome\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n\n<!-- \nNewPP limit report\nParsed by mw1242\nCached time: 20180901085638\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.232 seconds\nReal time usage: 0.255 seconds\nPreprocessor visited node count: 1028/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 33455/2097152 bytes\nTemplate argument size: 81/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 32659/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.103/10.000 seconds\nLua memory usage: 3.02 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  165.953      1 Template:Reflist\n100.00%  165.953      1 -total\n 77.89%  129.262     13 Template:Cite_journal\n  1.17%    1.945      1 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:57392784-0!canonical and timestamp 20180901085638 and revision id 849052049\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"CS1_French-language_sources_(fr)"},{"sortkey":"","*":"Syndromes"},{"sortkey":"","*":"Autosomal_dominant_disorders"},{"sortkey":"","*":"Transcription_factor_deficiencies"}],"links":[{"ns":0,"exists":"","*":"Acute myeloid leukemia"},{"ns":0,"exists":"","*":"Anemia"},{"ns":0,"exists":"","*":"Aplastic anemia"},{"ns":0,"exists":"","*":"Autosomal dominant"},{"ns":0,"exists":"","*":"Blood"},{"ns":0,"exists":"","*":"Bone marrow biopsy"},{"ns":0,"exists":"","*":"Bone marrow examination"},{"ns":0,"exists":"","*":"Bone marrow failure"},{"ns":0,"exists":"","*":"C-terminus"},{"ns":0,"exists":"","*":"Cell nucleus"},{"ns":0,"exists":"","*":"Cellular differentiation"},{"ns":0,"exists":"","*":"Chromosome 3"},{"ns":0,"exists":"","*":"Chromosome 7"},{"ns":0,"exists":"","*":"Chronic myelomonocytic leukemia"},{"ns":0,"exists":"","*":"Coding region"},{"ns":0,"exists":"","*":"Complete blood count"},{"ns":0,"exists":"","*":"Copy number analysis"},{"ns":0,"exists":"","*":"DNA"},{"ns":0,"exists":"","*":"DNA sequencing"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Embryogenesis"},{"ns":0,"exists":"","*":"Endothelium"},{"ns":0,"exists":"","*":"Enhancer (genetics)"},{"ns":0,"exists":"","*":"Epicanthic folds"},{"ns":0,"exists":"","*":"Erythrocytes"},{"ns":0,"exists":"","*":"FLI1"},{"ns":0,"exists":"","*":"Fluid"},{"ns":0,"exists":"","*":"GATA2"},{"ns":0,"exists":"","*":"GATA2 deficiency"},{"ns":0,"exists":"","*":"GATA transcription factor"},{"ns":0,"exists":"","*":"GFI1"},{"ns":0,"exists":"","*":"Gain-of-function mutation"},{"ns":0,"exists":"","*":"Gene expression"},{"ns":0,"exists":"","*":"Genetic disorder"},{"ns":0,"exists":"","*":"Haploinsufficiency"},{"ns":0,"exists":"","*":"Hematological disorders"},{"ns":0,"exists":"","*":"Hematopoiesis"},{"ns":0,"exists":"","*":"Hematopoietic stem cell transplantation"},{"ns":0,"exists":"","*":"Hemogenic endothelium"},{"ns":0,"exists":"","*":"High-throughput sequencing"},{"ns":0,"exists":"","*":"Hydrocele"},{"ns":0,"exists":"","*":"Hypotelorism"},{"ns":0,"exists":"","*":"Immunodeficiency"},{"ns":0,"exists":"","*":"Intron"},{"ns":0,"exists":"","*":"LYL1"},{"ns":0,"exists":"","*":"Leukemic"},{"ns":0,"exists":"","*":"Lymphatic system"},{"ns":0,"exists":"","*":"Lymphedema"},{"ns":0,"exists":"","*":"Lymphocyte"},{"ns":0,"exists":"","*":"MYB (gene)"},{"ns":0,"exists":"","*":"Macrophages"},{"ns":0,"exists":"","*":"MonoMAC"},{"ns":0,"exists":"","*":"Monocyte"},{"ns":0,"exists":"","*":"Monosomy"},{"ns":0,"exists":"","*":"Myelodysplastic syndrome"},{"ns":0,"exists":"","*":"N-terminus"},{"ns":0,"exists":"","*":"Neutropenia"},{"ns":0,"exists":"","*":"Nucleic acid sequence"},{"ns":0,"exists":"","*":"Nucleotide sequence"},{"ns":0,"exists":"","*":"Online Mendelian Inheritance in Man"},{"ns":0,"exists":"","*":"PU.1"},{"ns":0,"exists":"","*":"Perilymphatic space"},{"ns":0,"exists":"","*":"Platelet"},{"ns":0,"exists":"","*":"Pleiotropy"},{"ns":0,"exists":"","*":"Precancerous condition"},{"ns":0,"exists":"","*":"Progenitor cell"},{"ns":0,"exists":"","*":"Progenitor cells"},{"ns":0,"exists":"","*":"Promoter (genetics)"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"RUNX1"},{"ns":0,"exists":"","*":"Sanger sequencing"},{"ns":0,"exists":"","*":"Semicircular canals"},{"ns":0,"exists":"","*":"Sensorineural hearing loss"},{"ns":0,"exists":"","*":"Stem cell"},{"ns":0,"exists":"","*":"Structural motif"},{"ns":0,"exists":"","*":"TAL1"},{"ns":0,"exists":"","*":"Thrombocytopenia"},{"ns":0,"exists":"","*":"Transactivation domain"},{"ns":0,"exists":"","*":"Transcription factor"},{"ns":0,"exists":"","*":"Vertebrates"},{"ns":0,"exists":"","*":"Warts"},{"ns":0,"exists":"","*":"Webbed neck"},{"ns":0,"exists":"","*":"Zinc finger"}],"templates":[{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":["Lock-green.svg"],"externallinks":["//www.ncbi.nlm.nih.gov/pmc/articles/PMC5391620","//doi.org/10.1182/blood-2016-09-687889","//www.ncbi.nlm.nih.gov/pubmed/28179280","//doi.org/10.1097/MPH.0000000000000995","//www.ncbi.nlm.nih.gov/pubmed/29189513","//doi.org/10.1007/s12185-017-2285-2","//www.ncbi.nlm.nih.gov/pubmed/28643018","//doi.org/10.1053/j.seminhematol.2017.05.002","//www.ncbi.nlm.nih.gov/pubmed/28637621","//doi.org/10.1038/ng.923","//www.ncbi.nlm.nih.gov/pubmed/21892158","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5391619","//doi.org/10.1182/blood-2016-09-687871","//www.ncbi.nlm.nih.gov/pubmed/28179282","//www.ncbi.nlm.nih.gov/pubmed/295075","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3472596","//doi.org/10.1242/dev.080440","//www.ncbi.nlm.nih.gov/pubmed/23048181","//doi.org/10.1002/ajmg.a.33445","//www.ncbi.nlm.nih.gov/pubmed/20803646","//doi.org/10.1080/10245332.2017.1294551","//www.ncbi.nlm.nih.gov/pubmed/28271814","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4323616","//doi.org/10.1016/j.beha.2014.11.004","//www.ncbi.nlm.nih.gov/pubmed/25659730","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4342850","//doi.org/10.1097/ACI.0000000000000126","//www.ncbi.nlm.nih.gov/pubmed/25397911","https://www.ncbi.nlm.nih.gov/gene/2624"],"sections":[{"toclevel":1,"level":"2","line":"History","number":"1","index":"1","fromtitle":"Emberger_syndrome","byteoffset":6168,"anchor":"History"},{"toclevel":1,"level":"2","line":"<i>GATA2</i> gene","number":"2","index":"2","fromtitle":"Emberger_syndrome","byteoffset":8259,"anchor":"GATA2_gene"},{"toclevel":1,"level":"2","line":"GATA2 transcription factor","number":"3","index":"3","fromtitle":"Emberger_syndrome","byteoffset":10313,"anchor":"GATA2_transcription_factor"},{"toclevel":1,"level":"2","line":"Pathophysiology","number":"4","index":"4","fromtitle":"Emberger_syndrome","byteoffset":12601,"anchor":"Pathophysiology"},{"toclevel":1,"level":"2","line":"Clinical signs and symptoms","number":"5","index":"5","fromtitle":"Emberger_syndrome","byteoffset":14422,"anchor":"Clinical_signs_and_symptoms"},{"toclevel":1,"level":"2","line":"Diagnosis","number":"6","index":"6","fromtitle":"Emberger_syndrome","byteoffset":16658,"anchor":"Diagnosis"},{"toclevel":1,"level":"2","line":"Treatment","number":"7","index":"7","fromtitle":"Emberger_syndrome","byteoffset":18028,"anchor":"Treatment"},{"toclevel":1,"level":"2","line":"Prognosis","number":"8","index":"8","fromtitle":"Emberger_syndrome","byteoffset":20559,"anchor":"Prognosis"},{"toclevel":1,"level":"2","line":"References","number":"9","index":"9","fromtitle":"Emberger_syndrome","byteoffset":21333,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Emberger syndrome","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q55610804"}]}}